Epitalon
Epitalon is a synthetic four-amino-acid peptide marketed to slow aging and lengthen telomeres. Most of the research comes from one Russian laboratory group, with limited independent replication, and there are no trials showing it changes human aging, disease or lifespan. Since October 2026 it can be compounded on prescription by injection under an interim HHS policy; that is not approval.
Epitalon's telomere and longevity claims versus the evidence: a small single-group literature, no aging trials, and its 2026 U.S. status.
Big longevity claims resting on a small literature from one research tradition.
Key takeaways
- Lifespan findings come from animals.
- Telomere and telomerase findings come mostly from cell and animal work by one group.
- No human trials of aging, disease prevention or lifespan outcomes exist.
- Covered by the 2026 interim policy by injection, in intermittent courses only.
Why one research group is not enough
When most of a compound's literature comes from the people who developed it, independent replication matters even more. Results that hold up only in one laboratory's hands often narrow or disappear when others test them under blinded conditions.
Telomeres are a marker, not an outcome
Telomere length is associated with age, but changing a marker does not show that health or lifespan change. Longevity claims need trials that measure disease, function or survival, and none exist for Epitalon.
Our approach
Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.
Frequently asked questions
Does Epitalon slow aging?
There is no human trial evidence that it does. Lifespan effects have been reported only in animals, mostly by its developers' group.
Is Epitalon legal?
Since 28 October 2026, a licensed pharmacist or physician in the U.S. can compound it for an individual patient with a prescription, by injection in intermittent courses, under an interim HHS policy. It is not FDA-approved, and 'research use only' products are not covered.
Related on Beiing
- Peptides and healthy aging - Longevity marketing versus longevity research.
- The evidence ladder - Where Epitalon sits next to other peptides.
- How Beiing rates peptide evidence - The five evidence levels used in this section.
- Peptides & Human Biology - The hub for every page in this section.
Sources
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register document 2026-22192, docket HHS-OASH-2026-0496) - U.S. Department of Health and Human Services, via the Federal Register
- PubMed: published research on Epitalon (Epithalon, AEDG peptide) - U.S. National Library of Medicine
- Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration
- FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.